Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors.
Morimoto S, Oka Y, Tsuboi A, Tanaka Y, Fujiki F, Nakajima H, Hosen N, Nishida S, Nakata J, Nakae Y, Maruno M, Myoui A, Enomoto T, Izumoto S, Sekimoto M, Kagawa N, Hashimoto N, Yoshimine T, Oji Y, Kumanogoh A, Sugiyama H. Morimoto S, et al. Cancer Sci. 2012 Mar;103(3):408-14. doi: 10.1111/j.1349-7006.2011.02163.x. Epub 2012 Jan 17. Cancer Sci. 2012. PMID: 22126448 Free PMC article.
Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H, Masuda T, Fukuda Y, Kawakatsu M, Morimoto S, Katagiri T, Tatsumi N, Hosen N, Shirakata T, Nishida S, Kawakami Y, Udaka K, Kawase I, Oji Y, Sugiyama H. Li Z, et al. Among authors: morimoto s. Microbiol Immunol. 2008 Nov;52(11):551-8. doi: 10.1111/j.1348-0421.2008.00069.x. Microbiol Immunol. 2008. PMID: 19090835 Free article.
Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.
Nakajima H, Oka Y, Tsuboi A, Tatsumi N, Yamamoto Y, Fujiki F, Li Z, Murao A, Morimoto S, Hosen N, Shirakata T, Nishida S, Kawase I, Isaka Y, Oji Y, Sugiyama H. Nakajima H, et al. Among authors: morimoto s. Vaccine. 2012 Jan 17;30(4):722-9. doi: 10.1016/j.vaccine.2011.11.074. Epub 2011 Nov 29. Vaccine. 2012. PMID: 22133512
Functional human Th17 clones with WT1-specific helper activity.
Tachino S, Fujiki F, Oka Y, Tsuboi A, Morimoto S, Lin YH, Tamanaka T, Kondo K, Nakajima H, Nishida S, Hosen N, Oji Y, Kumanogoh A, Sugiyama H. Tachino S, et al. Among authors: morimoto s. Cancer Immunol Immunother. 2013 Apr;62(4):801-10. doi: 10.1007/s00262-012-1385-3. Epub 2012 Dec 29. Cancer Immunol Immunother. 2013. PMID: 23275045 Free PMC article.
HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
Lin Y, Fujiki F, Katsuhara A, Oka Y, Tsuboi A, Aoyama N, Tanii S, Nakajima H, Tatsumi N, Morimoto S, Tamanaka T, Tachino S, Hosen N, Nishida S, Oji Y, Kumanogoh A, Sugiyama H. Lin Y, et al. Among authors: morimoto s. J Immunother. 2013 Apr;36(3):159-70. doi: 10.1097/CJI.0b013e3182873581. J Immunother. 2013. PMID: 23502763
In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity.
Nakata J, Nakano K, Okumura A, Mizutani Y, Kinoshita H, Iwai M, Hasegawa K, Morimoto S, Fujiki F, Tatsumi N, Nakajima H, Nakae Y, Nishida S, Tsuboi A, Oji Y, Oka Y, Sugiyama H, Kumanogoh A, Hosen N. Nakata J, et al. Among authors: morimoto s. Leukemia. 2014 Jun;28(6):1316-25. doi: 10.1038/leu.2013.374. Epub 2013 Nov 13. Leukemia. 2014. PMID: 24336127
Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K, Tsuboi A, Oka Y, Yanagisawa S, Toyama Y, Ikegami M, Kitagawa T, Eguchi H, Wada H, Nagano H, Nakata J, Nakae Y, Hosen N, Oji Y, Tanaka T, Kawase I, Kumanogoh A, Sakamoto J, Doki Y, Mori M, Ohkusa T, Tajiri H, Sugiyama H. Nishida S, et al. Among authors: morimoto s. J Immunother. 2014 Feb-Mar;37(2):105-14. doi: 10.1097/CJI.0000000000000020. J Immunother. 2014. PMID: 24509173 Free PMC article. Clinical Trial.
Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.
Katsuhara A, Fujiki F, Aoyama N, Tanii S, Morimoto S, Oka Y, Tsuboi A, Nakajima H, Kondo K, Tatsumi N, Nakata J, Nakae Y, Takashima S, Nishida S, Hosen N, Sogo S, Oji Y, Sugiyama H. Katsuhara A, et al. Among authors: morimoto s. Anticancer Res. 2015 Mar;35(3):1251-61. Anticancer Res. 2015. PMID: 25750272
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Hashimoto N, Tsuboi A, Kagawa N, Chiba Y, Izumoto S, Kinoshita M, Kijima N, Oka Y, Morimoto S, Nakajima H, Morita S, Sakamoto J, Nishida S, Hosen N, Oji Y, Arita N, Yoshimine T, Sugiyama H. Hashimoto N, et al. Among authors: morimoto s. Cancer Immunol Immunother. 2015 Jun;64(6):707-16. doi: 10.1007/s00262-015-1674-8. Epub 2015 Mar 14. Cancer Immunol Immunother. 2015. PMID: 25772149 Free PMC article. Clinical Trial.
2,118 results